Adiponectin and leptin levels in Chinese patients with hiv-related lipodystrophy: A 30-month prospective study

AIDS Research and Human Retroviruses

Volumn 25, Issue 12, 2009, Pages 1265-1272

  Luo, Ling ^a   Zhang, Lu ^a   Tao, Meimei ^a   Qiu, Zhifeng ^a   Xie, Jing ^a   Han, Yang ^a   Li, Ming ^a   Li, Taisheng ^a  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; DIDANOSINE; EFAVIRENZ; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INDINAVIR; INSULIN; LAMIVUDINE; LEPTIN; NEVIRAPINE; STAVUDINE; TRIACYLGLYCEROL; ZIDOVUDINE;

ADULT; ARTICLE; BODY FAT DISTRIBUTION; CHINESE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; FEMALE; GLUCOSE BLOOD LEVEL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSULIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; TRIACYLGLYCEROL BLOOD LEVEL;

ADIPONECTIN; ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ASIAN CONTINENTAL ANCESTRY GROUP; CASE-CONTROL STUDIES; FEMALE; FOLLOW-UP STUDIES; HIV-1; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; INSULIN; LEPTIN; LOGISTIC MODELS; MALE; PROSPECTIVE STUDIES; RISK FACTORS; TRIGLYCERIDES;

EID: 73149092575     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2009.0072     Document Type: Article

References (33)

1. Carr A, Samaras K, Chisholm DJ, and Cooper DA: Abnormal fat distribution and use of protease inhibitors. Lancet 1998;351:1736.
2. Mallon PW, Cooper DA, and Carr AL: HIV-associated lipodystrophy. HIV Med 2001;2:166-173.
3. Duran S, Savès M, Spire B, Cailleton V, Sobel A, Carrieri P, Salmon D, Moatti JP, Leport C, and the APROCO Study Group: Failure to maintain long-term adherence to highly active antiretroviral therapy: The role of lipodystrophy. AIDS 2001;15:2441-2444.
4. d'Arminio A, Sabin CA, Phillips AN, Reiss P, Weber R, Kirk O, El-Sadr W, De Wit S, Mateu S, Petoumenos K, Dabis F, Pradier C, Morfeldt L, Lundgren JD, Friis-Møller N, and the Writing Committee of the D:A:D: Study Group: Cardio- and cerebrovascular events in HIV-infected persons. AIDS 2004;18:1811-1817.
5. Friis-Møller N, Sabin CA, Weber R, d'Arminio Monforte A, El-Sadr WM, Reiss P, Thiébaut R, Morfeldt L, De Wit S, Pradier C, Calvo G, Law MG, Kirk O, Phillips AN, and Lundgren JD: Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003;349:1993-2003.
6. FRAM Study Investigators: Fat distribution in men with HIV infection. J Acquir Immune Defic Syndr 2005;40:121-131.
7. FRAM Study Investigators: Fat distribution in women with HIV infection. J Acquir Immune Defic Syndr 2006;42:562-571.
8. Haque WA, Shimomura I, Matsuzawa Y, and Garg A: Serum adiponectin and leptin in patients with lipodystrophies. J Clin Endocrinol Metab 2002;87:2395-2398.
9. Schwenk A: Methods of assessing body shape and composition in HIV-associated lipodystrophy. Curr Opin Infect Dis 2002;15:9-16.
10. Lichtenstein KA, Delaney KM, Armon C, Ward DJ, Moorman AC, Wood KC, Holmberg SD, and the HIV Outpatient Study Investigators: Incidence of and risk factors for lipoatrophy (abnormal fat loss) in ambulatory HIV-1-infected patients. J Acquir Immune Defic Syndr 2003;32:48-56.
11. Estrada V, Martínez-Larrad MT, González-Sánchez JL, de Villar NG, Zabena C, Fernández C, and Serrano-Ríos M: Lipodystrophy and metabolic syndrome in HIV-infected patients treated with antiretroviral therapy. Metab Clin Exp 2006;55:940-945.
12. Li M, Wu CY, Zhan ZW, Li XG, Zhang K, and Xiang HD: Leptin and clustering of the components of risk factors for metabolic syndrome. Zhonghua Yu Fang Yi Xue Za Zhi 2004;38:226-230.
13. Yin JH, Li M, Yang J, and Wu CY: Primary culture of human omental preadipocytes and study of their biological properties. Zhonghua Yi Xue Za Zhi 2007;27:838-841.
14. Xiao X, Zhang ZX, Cohen HJ, Wang H, Li W, Wang T, Xu T, Liu A, Gai MY, Ying S, Schmitz O, and Yi Z: Evidence of a relationship between infant birth weight and later diabetes and impaired glucose regulation in a Chinese population. Diabetes Care 2008;31:483-487.
15. Chen D, Anoop M, and Garg A: Clinical review 153: Lipodystrophy in human immunodeficiency virus-infected patients. J Clin Endocrinol Metab 2002;87:4845-4856.
16. Tong Q, Sankalé JL, Hadigan CM, Tan G, Rosenberg ES, Kanki PJ, Grinspoon SK, and Hotamisligil GS: Regulation of adiponectin in human immunodeficiency virus-infected patients: Relationship to body composition and metabolic indices. J Clin Endocrinol Metab 2003;88:1559-1564.
17. Kingsley L, Smit E, and Riddler S: Prevalence of lipodystrophy and metabolic abnormalities in the multicenter AIDS cohort study (MACS). In: Program and Abstracts of the 8th Conference on Retroviruses and Opportunistic Infections (Chicago). Virginia: Foundation for Retrovirology and Human Health, 2001 [abstract 538].
18. Mahajan AP, Tashima KT, Bausserman LL, Flynn MM, and Carpenter CC: Plateau in body habitus changes and serum lipid abnormalities in HIV-positive women on highly active antiretroviral therapy: A 3.5-year study. J Acquir Immune Defic Syndr 2001;28:332-335.
19. Scherer PE, Williams S, Fogliano M, Baldini G, and Lodish HF: A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem 1995;270:26746-26749.
20. Tsiodras S and Mantzoros C: Leptin and adiponectin in the HIV associated metabolic syndrome: Physiologic and therapeutic implications. Am J Infect Dis 2006;2:141-152.
21. Sutinen J, Korsheninnikova E, Funahashi T, Matsuzawa Y, Nyman T, and Yki-Järvinen H: Circulating concentration of adiponectin and its expression in subcutaneous adipose tissue in patients with highly active antiretroviral therapyassociated lipodystrophy. J Clin Endocrinol Metab 2003; 88:1907-1910.
22. Addy CL, Gavrila A, Tsiodras S, Brodovicz K, Karchmer AW, and Mantzoros CS: Hypoadiponectinemia is associated with insulin resistance, hypertriglyceridemia and fat redistribution in human immunodeficiency virus-infected patients treated with highly active antiretroviral therapy. J Clin Endocrinol Metab 2003;88:627-636.
23. Gervasoni C, Ridolfo AL, Trifirò G, Santambrogio S, Norbiato G, Musicco M, Clerici M, Galli M, and Moroni M: Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapy. AIDS 1999;13:465-471.
24. Lihn AS, Richelsen B, Pedersen SB, Haugaard SB, Rathje GS, Madsbad S, and Andersen O: Increased expression of TNFa, IL-6 and IL-8 in HALS: Implications for reduced adiponectin expression and plasma levels. Am J Physiol Endocrinol Metab 2003;285:e1072-1080.
25. Bruun JM, Lihn AS, Verdich C, Pedersen SB, Toubro S, Astrup A, and Richelsen B: Regulation of adiponectin by adipose tissue-derived cytokines: In vivo and in vitro investigations in humans. Am J Physiol Endocrinol Metab 2003;285:e527-533.
26. Jones SP, Janneh O, Back DJ, and Pirmohamed M: Altered adipokine response in murine 3T3-F442A adipocytes treated with protease inhibitors and nucleoside reverse transcriptase inhibitors. Antivir Ther 2005;10:207-213.
27. Kosmiski L, Kuritzkes D, Lichtenstein K, and Eckel R: Adipocyte- derived hormone levels in HIV lipodystrophy. Antivir Ther 2003;8:9-15.
28. Mynarcik DC, Combs T, McNurlan MA, Scherer PE, Komaroff E, and Gelato MC: Adiponectin and leptin levels in HIV-infected subjects with insulin resistance and body fat redistribution. J Acquir Immune Defic Syndr 2002;31:514-520.
29. Dubé MP, Komarow L, Mulligan K, Grinspoon SK, Parker RA, Robbins GK, Roubenoff R, Tebas P, and the Adult Clinical Trials Group 384: Long-term body fat outcomes in antiretroviral-naive participants randomized to nelfinavir or efavirenz or both plus dual nucleosides. Dual X-ray absorptiometry results from A5005s, a substudy of Adult Clinical Trials Group 384. J Acquir Immune Defic Syndr 2007;45:508-514.
30. Joly V, Flandre P, Meiffredy V, Leturque N, Harel M, Aboulker JP, and Yeni P: Increased risk of lipoatrophy under stavudine in HIV-1 infected patients: Results of a substudy from a comparative trial. AIDS 2002;16:2447-2454.
31. van der VM, Casula M, and Ruiter JP: Relation between use of nucleoside reverse transcriptase inhibitors, mitochondrial DNA depletion, and severity of lipoatrophy: Results from a randomized trial comparing stavudine and zidovudinebased antiretroviral therapy. In: Program and Abstracts of the 10th Conference on Retroviruses and Opportunistic Infections (Boston). Virginia: Foundation for Retrovirology and Human Health, 2003, p. 323 [abstract 739].
32. Lichtenstein KA, Ward DJ, Moorman AC, Delaney KM, Young B, Palella FJ Jr, Rhodes PH, Wood KC, Holmberg SD, and the HIV Outpatient Study Investigators: Clinical assessment of HIV-associated lipodystrophy in an ambulatory population. AIDS 2001;15:1389-1398.
33. Lichtenstein KA, Delaney KM, Armon C, Ward DJ, Moorman AC, Wood KC, Holmberg SD, and the HIV Outpatient Study Investigators: Incidence of and risk factors for lipoatrophy (abnormal fat loss) in ambulatory HIV-1-infected patients. J Acquir Immune Defic Syndr 2003;32:48-56.